A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Biological dosimetry in lung cancer (LC) patients treated with fractionated radiotherapy (RT) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014
Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
The role of radiotherapy (RTH) in long-term survival limited disease (LD) small cell lung cancer (SCLC) patients (pts) treated in the National TB and Lung Diseases Research Institute Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013
Outcomes of radical treatment of early stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013